Matrixx Initiatives (MTXX) Receives Informal Inquiry from SEC On FDA Zicam Issues
Matrixx Initiatives Inc. (Nasdaq: MTXX) disclosed in an SEC filing received an informal inquiry from the Securities and Exchange Commission (SEC) requesting certain documents and information relating to the previously disclosed June 16, 2009 warning letter issued to the Company by the United States Food and Drug Administration (FDA).
The Company will fully cooperate with the SEC in this informal inquiry,
Shares of MTXX collapsed on June 16 after the FDA sent the company a warning letter saying the products "may pose a serious risk to consumers who use them." The FDA said it has received more than 130 reports of anosmia, (loss of sense of smell, which in some cases can be long-lasting or permanent), associated with use of Zicam.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
